Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions

Leprosy Review

Volumn 71, Issue SUPPL., 2000, Pages

  Kaplan, G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; PLACEBO; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DROWSINESS; DRUG HALF LIFE; DRUG POTENCY; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOSTIMULATION; LEPROSY; MONONUCLEAR CELL; PERIPHERAL CIRCULATION; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; TERATOGENICITY; TUBERCULOSIS;

EID: 0034494295     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.20000082     Document Type: Conference Paper

References (19)

1. Thalidomide in the treatment of lepra reactions
2. Thalidomide selectively inhibits TNFα production by stimulated human monocytes
3. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation
4. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
5. Thalidomide treatment reduces TNF-α production and enhances weight gain in patients with pulmonary tuberculosis
6. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
7. Thalidomide inhibits the replication of human immunodeficiency virus type-1
8. Thalidomide-induced antigen-specific immune stimulation in patients with HIV-1 and tuberculosis
9. Immune stimulation in scleroderma patients treated with thalidomide
10. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
11. Thalidomide for the treatment of patients with AIDS-associated wasting
12. Adverse reactions to thalidomide in patients infected with the human immunodeficiency virus
13. Selection of novel analogues of thalidomide with enhanced TNF-α inhibitory activity
14. Structural modifications of thalidomide produce analogs with enhanced TNF inhibitory activity
15. Thalidomide protects against LPS-induced shock
16. Thalidomide analog CC1069 inhibits development of rat adjuvant arthritis
17. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-α
18. Amino-substituted thalidomide analogues: Potent inhibitors of TNF-α production
19. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset